Palbociclib: an approval at last for HER2-negative breast cancer

Future Oncol. 2016 May;12(9):1097-100. doi: 10.2217/fon-2015-0056. Epub 2016 Mar 18.

Authors

Ioannis Zerdes^{1

2}, Demosthenes E Ziogas^{1

3}, Efstathios G Lykoudis⁴, Dimitrios H Roukos^{1

2

5}

Affiliations

¹ Centre for Biosystems & Genomic Network Medicine, University of Ioannina, Ioannina, Greece.
² Department of Surgery, Ioannina University Hospital, Ioannina, Greece.
³ Department of Surgery, 'G Hatzikosta' General Hospital, Ioannina, Greece.
⁴ Department of Plastic Surgery, Ioannina University School of Medicine, Ioannina, Greece.
⁵ Biomedical Research Foundation of the Academy of Athens (BRFAA), Athens, Greece.

PMID: 26987714
DOI: 10.2217/fon-2015-0056

No abstract available

Keywords: HER2-negative; breast cancer; metastasis; palbociclib.

Publication types

Editorial

MeSH terms

Antineoplastic Agents / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / metabolism*
Female
Humans
Piperazines / therapeutic use*
Pyridines / therapeutic use*
Receptor, ErbB-2 / metabolism*

Substances

Antineoplastic Agents
Piperazines
Pyridines
ERBB2 protein, human
Receptor, ErbB-2
palbociclib